title: Therapy-related acute promyelocytic leukemia following etoposide-based chemotherapy in non-seminomatous germ cell tumor.
abstract: Therapy related AML (t- AML) accounts for 10-20% of all cases of AML. Cytotoxic agents implicated are alkylating agents, topoisomerase II inhibitors and rarely anti metabolites and anti tubulin agents. A growing incidence of therapy related acute promyelocytic leukemia (t-APL) has been reported over the last few decades in malignant and non malignant conditions. To the best of our knowledge this is the first t-APL case report to be reported in NSGCT post etoposide based therapy.
authors.forename: T N
authors.initials: TN
authors.lastname: Kumar
authors.affiliation: Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India.
authors.forename: L V
authors.initials: LV
authors.lastname: Gandhi
authors.forename: D
authors.initials: D
authors.lastname: Raghunadharao
authors.forename: G
authors.initials: G
authors.lastname: Sadashivudu
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D020732:Cytogenetic Analysis; D005047:Etoposide / Q000627:therapeutic use*; D017809:Fatal Outcome; D006801:Humans; D059785:Karyotype; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000235:genetics; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D013736:Testicular Neoplasms; D059005:Topoisomerase II Inhibitors / Q000627:therapeutic use*; D014178:Translocation, Genetic
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D059005:Topoisomerase II Inhibitors; D005047:Etoposide